On Oct 22, major Wall Street analysts update their ratings for $Procter & Gamble (PG.US)$, with price targets ranging from $180 to $191.
Morgan Stanley analyst Dara Mohsenian maintains with a buy rating, and adjusts the target price from $174 to $191.
BofA Securities analyst Bryan Spillane maintains with a buy rating, and maintains the target price at $185.
Citi analyst Filippo Falorni maintains with a buy rating.
Evercore analyst Robert Ottenstein maintains with a buy rating, and adjusts the target price from $180 to $183.
TD Cowen analyst Robert Moskow maintains with a buy rating, and maintains the target price at $189.
Furthermore, according to the comprehensive report, the opinions of $Procter & Gamble (PG.US)$'s main analysts recently are as follows:
The prevailing discussion post-Procter & Gamble's first quarter results, which aligned closely with expectations and featured moderate organic sales growth with a slight earnings per share advantage stemming from factors below the profit line, revolves around the sustainable level of the company's organic growth. Highlighting 'solid execution' and anticipating more favorable comparisons, especially in regions such as China and the Middle East, the expectation is for a revival in organic sales growth.
Procter & Gamble is achieving impressive comparable performance in the U.S., Europe, and key markets in Latin America, which collectively account for approximately 85% of its sales and presumably a similar share of profits. Nevertheless, adjustments have been made to the company's Q2 estimates to reflect additional risks associated with the Chinese market, as mentioned by an analyst in a post-earnings discussion.
Here are the latest investment ratings and price targets for $Procter & Gamble (PG.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月22日，多家華爾街大行更新了$寶潔 (PG.US)$的評級，目標價介於180美元至191美元。
摩根士丹利分析師Dara Mohsenian維持買入評級，並將目標價從174美元上調至191美元。
美銀證券分析師Bryan Spillane維持買入評級，維持目標價185美元。
花旗分析師Filippo Falorni維持買入評級。
Evercore分析師Robert Ottenstein維持買入評級，並將目標價從180美元上調至183美元。
TD Cowen分析師Robert Moskow維持買入評級，維持目標價189美元。
此外，綜合報道，$寶潔 (PG.US)$近期主要分析師觀點如下：
關於寶潔公司第一季度成績的討論主要集中在公司有機銷售增長略有優勢的預期中，這一預期與之前的預期十分接近，有機銷售增長以及略帶的每股收益優勢通常來自於利潤線以下的因素。討論圍繞公司有機銷售增長的可持續水平展開，強調了'穩固執行'，並預計在中國和中東等地區，特別是在更加有利的對比中，有望看到有機銷售增長的復甦。
寶潔公司在美國、歐洲以及拉丁美洲等主要市場取得了令人印象深刻的可比表現，這些市場共佔其銷售額的約85%，據推測也佔據類似份額的利潤。然而，爲了反映與中國市場相關的額外風險，公司對第二季度的估計進行了調整，一位分析師在盈利後的討論中提到了這一點。
以下爲今日8位分析師對$寶潔 (PG.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
